| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43TR004549 | MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes. | 000 | 1 | NIH | 10/23/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $913,659 ) |
| | 2024 | 2024 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44TR004230 | Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk | 000 | 3 | NIH | 6/27/2024 | $913,659 |
| | 2024 | 2023 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43TR004549 | MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes. | 000 | 1 | NIH | 8/9/2024 | $0 |
| | 2024 | 2023 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DK130647 | A 2D Intestinal Crypt Platform for Compound Screens | 000 | 3 | NIH | 4/29/2024 | $0 |
| | 2024 | 2022 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43DK130708 | A Mucus-producing Intestinal Epithelium Model for In Vitro Drug Absorption Testing | 000 | 1 | NIH | 3/11/2024 | $0 |
| | 2024 | 2022 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43TR004230 | Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk | 000 | 1 | NIH | 2/23/2024 | $0 |
| | 2024 | 2021 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DK121580 | Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system | 000 | 3 | NIH | 1/25/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $3,145,637 ) |
| | 2023 | 2023 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DK130647 | A 2D Intestinal Crypt Platform for Compound Screens | 000 | 3 | NIH | 7/21/2023 | $900,267 |
| | 2023 | 2023 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44TR004234 | InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation | 000 | 2 | NIH | 3/31/2023 | $988,414 |
| | 2023 | 2023 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43TR004549 | MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes. | 000 | 1 | NIH | 8/14/2023 | $343,297 |
| | 2023 | 2023 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44TR004230 | Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk | 000 | 2 | NIH | 6/27/2023 | $913,659 |
| | 2023 | 2021 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43DK130647 | A 2D Intestinal Crypt Platform for Compound Screens | 000 | 1 | NIH | 6/26/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,531,298 ) |
| | 2022 | 2022 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43TR004230 | Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk | 000 | 1 | NIH | 6/23/2022 | $256,574 |
| | 2022 | 2022 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43DK130708 | A Mucus-producing Intestinal Epithelium Model for In Vitro Drug Absorption Testing | 000 | 1 | NIH | 5/6/2022 | $293,991 |
| | 2022 | 2022 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44TR004234 | InflammaGut: a drug-screenable co-culture system using gut-associated lymphocytes and autologous primary human gut epithelium that reports inflammation | 000 | 1 | NIH | 4/30/2022 | $992,302 |
| | 2022 | 2022 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DK130647 | A 2D Intestinal Crypt Platform for Compound Screens | 000 | 2 | NIH | 9/22/2022 | $988,431 |
| | 2022 | 2020 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43DK125155 | Generating drug-screenable primary human intestinal epithelium by gene-editing and transgenesis | 000 | 1 | NIH | 4/28/2022 | $0 |
| | 2022 | 2020 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DK117763 | Co-culture cassette for anaerobes and primary human intestinal epithelium | 000 | 3 | NIH | 6/1/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $955,884 ) |
| | 2021 | 2021 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R44DK121580 | Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system | 000 | 3 | NIH | 6/28/2021 | $699,341 |
| | 2021 | 2021 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43DK130647 | A 2D Intestinal Crypt Platform for Compound Screens | 000 | 1 | NIH | 6/30/2021 | $256,543 |
| | 2021 | 2018 | ALTIS BIOSYSTEMS, INC. | 6 DAVIS DR | DURHAM | NC | 27709-0003 | DURHAM | USA | R43DK117763 | Co-culture cassette for anaerobes and primary human intestinal epithelium | 000 | 1 | NIH | 3/9/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,704,652 ) |
| | 2020 | 2020 | ALTIS BIOSYSTEMS, INC. | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R44DK117763 | Co-culture cassette for anaerobes and primary human intestinal epithelium | 000 | 3 | NIH | 7/28/2020 | $745,742 |
| | 2020 | 2020 | ALTIS BIOSYSTEMS, INC. | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R43DK125155 | Generating drug-screenable primary human intestinal epithelium by gene-editing and transgenesis | 000 | 1 | NIH | 3/30/2020 | $245,920 |
| | 2020 | 2020 | ALTIS BIOSYSTEMS, INC. | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R44DK121580 | Developing an optimized cell based platform for assays of the gastrointestinal enteroendocrine system | 000 | 2 | NIH | 8/21/2020 | $712,990 |
|
| Issue Date FY: 2019 ( Subtotal = $970,689 ) |
| | 2019 | 2019 | ALTIS BIOSYSTEMS, INC. | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R44DK117763 | Co-culture cassette for anaerobes and primary human intestinal epithelium | 000 | 2 | NIH | 9/13/2019 | $747,640 |
| | 2019 | 2019 | ALTIS BIOSYSTEMS, INC. | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R44DK117763 | Co-culture cassette for anaerobes and primary human intestinal epithelium | 001 | 2 | NIH | 9/17/2019 | $0 |
| | 2019 | 2019 | ALTIS BIOSYSTEMS, INC. | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R43DK121580 | Developing a platform and optimized cell system for enteroendocrine cell-based assays and compound screening | 000 | 1 | NIH | 7/23/2019 | $223,049 |
| | 2019 | 2018 | ALTIS BIOSYSTEMS, INC. | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R43DK117763 | Co-culture cassette for anaerobes and primary human intestinal epithelium | 000 | 1 | NIH | 11/29/2018 | -$224,898 |
| | 2019 | 2018 | ALTIS BIOSYSTEMS, INC. | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R43DK117763 | Co-culture cassette for anaerobes and primary human intestinal epithelium | 001 | 1 | NIH | 11/30/2018 | $224,898 |
|
| Issue Date FY: 2018 ( Subtotal = $224,898 ) |
| | 2018 | 2018 | ALTIS BIOSYSTEMS LLC | 1289 N FORDHAM BLVD STE A234 | CHAPEL HILL | NC | 27514-6110 | ORANGE | USA | R43DK117763 | Co-culture cassette for anaerobes and primary human intestinal epithelium | 000 | 1 | NIH | 9/20/2018 | $224,898 |
|
|
